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Background
Adenosine has traditionally been utilized for coronary
hyperemia during myocardial perfusion assessment in
adults, however regadenoson has recently become more
popular [1]. With improved survival of congenital heart
disease (CHD), and increased diagnosis of acquired
heart disease (AHD), there’s an increasing need for
assessment of myocardial perfusion in pediatrics [2].
Only dipyridamole and adenosine have reportedly been
utilized as hyperemia stressors in CHD patients. As a
selective A2A agonist, regadenoson has a more favorable
side-effect profile and less stimulation of receptors asso-
ciated with bronchospasm, and decreased chronotropy
[1]. It is administered as an intravenous (IV) bolus and
thus only a single IV is required. Peak onset is at 60-90
seconds, with hyperemia lasting up to 6 minutes allow-
ing additional wall motion assessment [3].
Purpose
To observe the safety, feasibility and effectiveness of
regadenoson as a pharmacologic stressor for perfusion
CMR in a pilot cohort of CHD and pediatric AHD
patients, as part of an ongoing.
Methods
We reviewed our initial experience with regadenoson
stress CMR in 9 subjects (aged 16.6 +/- 1.6 yrs) with
CHD and pediatric AHD. All patients underwent stress
CMR due to clinical symptoms and/or signs suggestive
of ischemia. Cohort included 6 patients with D-TGA, 2
with coronary aneurysm, and 1 with coarctation.
Acquisition protocol
See table for full details. Heart rate and blood pressure
were monitored during CMR. Pharmacologic stress
obtained by injecting 400 mcg of regadenoson 60 sec-
onds prior to stress perfusion assessment. Rest and
stress myocardial perfusion were assessed during the
administration of 0.1 mmol/kg of gadolinium IV. Ventri-
cular wall motion was assessed with cine SSFP imaging.
Myocardial viability imaging was performed. Patients
were monitored for 2 hours after the study.
Data analysis
Myocardial perfusion and viability images were jointly
assessed by a pediatric cardiologist and radiologist. MR
images were assessed for WMA.
Results
All stress CMR examinations were completed unevent-
fully. Peak stress was achieved in all studies. There were
no serious adverse events. Resting heart rate was 63 +/-
12 beats per minute (bpm) and rose to a peak of
132 +/- 22 bpm.
One patient with D-TGA had a fixed perfusion defect
in the circumflex coronary artery distribution (fig 1),
and one patient with D-TGA had reversible subendocar-
dial perfusion defect in the left anterior descending
distribution.
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Conclusions
Regadenoson may be a safe, feasible and effective phar-
macologic stress agent for use in CMR of CHD and
pediatric AHD. The use of a single IV bolus, and the
advantage of a prolonged hyperemia makes it appealing
in pediatrics.
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Figure 1 Basal short-axis slice demonstrating perfusion defect in the posterior and lateral myocardium consistent with circumflex artery
occlusion(A). Corresponding myocardial viability. images demonstrated delayed-enhancement (B).
Figure 2 Acquisition Protocol used for wall motion analysis (WMA),
perfusion assessment and myocardial viability is listed.
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